NasdaqGS:TECHLife Sciences
The Bull Case For Bio-Techne (TECH) Could Change Following Renewed Analyst Support In A Soft Market
On 23 June 2026, TD Cowen analyst Kyle Boucher reiterated a positive view on Bio-Techne, describing it as a premier small to mid-cap option despite ongoing life sciences market softness and recent insider selling.
His comments, alongside a broader consensus that still sees moderate upside for the company despite funding and demand headwinds, suggest investors are reassessing how Bio-Techne is valued within a challenged sector.
Next, we'll examine how this renewed analyst confidence, despite...